|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.640 AUD | +1.54% |
|
+5.18% | +3.94% |
| 31/12 | Integral Diagnostics Chair Buys Shares | MT |
| 18/12 | Goldman Sachs Starts Integral Diagnostics at Sell with AU$2.10 Price Target | MT |
| Capitalization | 969M 651M 558M 519M 484M 903M 58.7B 5.97B 2.35B 28.08B 2.44B 2.39B 103B | P/E ratio 2026 * |
21.7x | P/E ratio 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise value | 1.3B 871M 746M 694M 647M 1.21B 78.52B 7.99B 3.14B 37.56B 3.27B 3.2B 138B | EV / Sales 2026 * |
1.61x | EV / Sales 2027 * | 1.5x |
| Free-Float |
83.6% | Yield 2026 * |
3.22% | Yield 2027 * | 3.84% |
Last Transcript: Integral Diagnostics Limited
| 1 day | +1.54% | ||
| 1 week | +5.18% | ||
| Current month | +3.94% | ||
| 1 month | +7.32% | ||
| 3 months | -0.38% | ||
| 6 months | +1.54% | ||
| Current year | +3.94% |
| 1 week | 2.48 |  | 2.64 |
| 1 month | 2.3 | | 2.64 |
| Current year | 2.48 | | 2.64 |
| 1 year | 1.91 | | 3.15 |
| 3 years | 1.64 | | 3.54 |
| 5 years | 1.64 | | 5.55 |
| 10 years | 1.04 | | 5.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Craig White
DFI | Director of Finance/CFO | - | 24/01/2022 |
Julian Gully
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2018 |
Nikki Valle
LAW | General Counsel | - | 14/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Raelene Murphy
BRD | Director/Board Member | 65 | 01/10/2017 |
Andrew Fay
BRD | Director/Board Member | 61 | 18/07/2022 |
Ingrid Player
BRD | Director/Board Member | 52 | 29/08/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.54% | +5.18% | -10.20% | -16.72% | 651M | |
| +0.49% | -0.83% | +34.54% | +477.79% | 32.57B | |
| +0.88% | +5.16% | -16.65% | -25.01% | 7.58B | |
| -2.37% | +2.94% | +11.01% | +289.54% | 5.9B | |
| -11.92% | -9.32% | +33.41% | +638.17% | 3.45B | |
| +2.90% | -5.40% | -0.76% | +30.86% | 2.56B | |
| +10.01% | +25.65% | +46.36% | -54.53% | 2.46B | |
| +20.00% | +37.03% | +109.25% | -17.23% | 2.28B | |
| -3.03% | -5.33% | - | - | 1.78B | |
| -5.09% | +3.39% | -15.44% | +20.33% | 1.62B | |
| Average | +2.76% | +3.19% | +21.28% | +149.25% | 6.09B | |
| Weighted average by Cap. | +1.34% | +1.02% | +25.54% | +325.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 805M 541M 463M 431M 402M 750M 48.75B 4.96B 1.95B 23.32B 2.03B 1.99B 85.51B | 854M 574M 491M 457M 426M 796M 51.71B 5.26B 2.07B 24.74B 2.15B 2.11B 90.71B |
| Net income | 47.15M 31.69M 27.13M 25.23M 23.52M 43.96M 2.86B 291M 114M 1.37B 119M 116M 5.01B | 56.85M 38.21M 32.72M 30.43M 28.37M 53M 3.44B 350M 138M 1.65B 143M 140M 6.04B |
| Net Debt | 327M 220M 188M 175M 163M 305M 19.82B 2.02B 793M 9.48B 825M 808M 34.77B | 310M 208M 178M 166M 155M 289M 18.76B 1.91B 751M 8.98B 781M 765M 32.91B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 2.640 $ | +1.54% | 339,743 |
| 12/01/26 | 2.600 $ | +2.36% | 345,855 |
| 09/01/26 | 2.540 $ | -0.39% | 492,111 |
| 08/01/26 | 2.550 $ | +1.59% | 424,631 |
| 07/01/26 | 2.510 $ | 0.00% | 491,913 |
Delayed Quote Australian S.E., 13 January 2026 at 04:10 pm AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IDX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition